ABSTRACT β-Defensins are antibiotic peptides involved in host defense at the epithelial surface. Three human β-defensins (hBDs)--hBD-1, hBD-2, and hBD-3--have been identified so far. We have characterized a new member of the β-defensin family, hBD-4, based on screening of genomic sequences and subsequent functional analysis. In contrast to hBD-1, hBD-2, and hBD-3, which are diffusely expressed throughout many organs, hBD-4 mRNA expression is confined to testis, stomach, uterus, neutrophils, thyroid, lung, and kidney. hBD-4 expression was up-regulated by infection with gram-positive and gram-negative bacteria in human respiratory epithelial cells, and in response to phorbol 12-myristate 13-acetate, but not in response to other inflammatory factors that up-regulate the expression of hBD-2 or hBD-3. Synthetic hBD-4 exhibits a selective, salt-sensitive spectrum of antimicrobial activity, and it represents one of the most active antimicrobial peptides against Pseudomonas aeruginosa (minimal inhibitory concentration: 4.1 µg/ml) known to date. This new defensin is chemotactic for human blood monocytes, but it is inactive on neutrophils and eosinophils. These findings demonstrate the existence of a family of β-defensin genes with different functions against diverse classes of microorganisms, regulated by different stimuli, and specific signal pathways, and confirm the relevance of antimicrobial peptides in host defense.
D β-Defensins contribute to early host defense against several bacterial and fungal pathogens, and although the exact mechanism of antimicrobial activity is still under discussion, it is an imposing detail that, so far, no acquired resistance against antimicrobial peptides could be observed. Besides this antimicrobial activity, a chemoattractant activity on both immature dentritic cells and memory T cells (9) , as well as for monocytes (7) , has been recently described, demonstrating that β-defensins may promote both innate and adaptive immune response.
Despite the relevance of β-defensins in host defense, only three human β-defensins (hBds) have been identified to date, and their regulation and functions have not yet been completely elucidated. hBD-1, the first hBD characterized, was isolated from large amounts of hemofiltrate (10) and is constitutively expressed in the urogenital and respiratory tracts (11) . In contrast, hBD-2, isolated from psoriatic skin by using an affinity chromatography procedure (12) , is present mainly in skin and the respiratory and gastrointestinal tracts, and its expression is notably increased by different bacteria and inflammatory factors (13, 14) . hBD-3 has been recently discovered by screening genomic sequences of the Human Genome Project (7) and isolated from skin (15) . This defensin is expressed in different epithelial and nonepithelial tissues, and its expression is inducible upon stimulation with interferon-γ, but not with other inflammatory cytokines or bacteria. The differences in the expression pattern, regulation of expression, and functional activity among these hBDs have suggested the picture of a family of homologous genes with different functions against diverse classes of microorganisms, regulated by different stimuli and signaling pathways. This concept was previously defined for the host defense system of Drosophila (16) , but it is still necessary to identify and characterize new members of the β-defensin family to confirm that this concept is also applicable to humans.
The advances of the Human Genome Project offer the opportunity to detect the sequential motifs of defensins and to further identify novel antimicrobial peptides. Because all the known defensins cluster on chromosome 8p23, the search may be restricted to a small segment in the sequences from the Human Genome Project. The evaluation of the biological functions of these antimicrobial peptides allows for the determination of their exact role as effector molecules of host defense as well as for the application of this knowledge for diagnostic and therapeutic approaches. Here, we report the gene structure, cDNA, expression, and its regulation, as well as biological activities of a new hBD, hBD-4, which exhibits a different way of induction and antimicrobial spectrum than do other hBDs.
MATERIALS AND METHODS

Identification and characterization of the genomic sequence of hBD-4
The amino acid sequence of hBD-2 (GenBank accession number: AF040153) was used as a template to perform a "basic local alignment search tool" (BLAST) search in the High Throughput Genomic (HTG) division of GenBank at the website of the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/BLAST), and several overlapping sequences were found. Clones containing the second exon of hBD-2 were further translated into the possible open reading frames by using the ORF Finder Program (http://www.ncbi.nlm.nih.gov/gorf/gorf.html). The amino acid sequences were then analyzed for the presence of the conserved β-defensin cysteine pattern by using the PattinProt program at http://pbil.ibcp.fr (17) . On the basis of these criteria, we focused on a sequence that we call hBD-4. Initially, only the putative exon 2 of hBD-4 was detected. For the promoter analysis, the 1200-bp upstream of the putative start of translation were aligned from all clones containing the sequence, and the resulting consensus bases were analyzed with the MatInspector program (http://www.genomatix.de) (18) . The putative cleavage sites of the prepropetide were predicted by using SignalP V2.0 (http://www.cbs.dtu.dk/services/SignalP-2.0/) (19).
Cloning of the hBD-4 cDNA
To clone the complete 5'-cDNA sequence, we performed RACE-PCR with the human lung Marathon-Ready cDNA kit (Clontech Laboratories, Palo Alto, CA), according to the manufacturer's instructions with gene-specific primers for hBD-4 (hBD-4-outer: 5-TCCAATTCTGTATTCTTGGCTGCGACAT-3', and hBD-4-inner: 5'-CAACGGGCAGTCCCATAACCACATATTC-3'). The PCR products were purified and cloned into pGEM-T vector (Promega, Madison, WI). Clones were subsequently sequenced on a Prism 310 Genetic Analyzer (Applied Biosystems, Foster City, CA) and aligned with the clones containing the sequence in the HTG division of GenBank in order to resolve discrepancies between the bases of all related sequences.
Quantification of hBD-4 expression by real-time quantitative RT-PCR
The distribution of the hBD-4 expression was evaluated by real-time reverse-transcription PCR using a Prism 7700 Sequence Detection System (TaqMan, Applied Biosystems). The principles of this technique as well as practical applications have been described elsewhere (20) (21) (22) (23) . Human total RNA from normal placenta, testis, trachea, heart, skeletal muscle, liver, thyroid gland, pancreas, lung, uterus, kidney, salivary gland, prostate, brain, cerebellum, adrenal gland, and mammary gland was purchased from Clontech Laboratories. Total RNA was extracted from a previously healthy individual through an organ donor program by using the guanidinium isothiocyanate method from esophagus, gastric antrum, gastric fundus, gastric corpus, jejunum, colon, rectum, and urinary bladder. In order to eliminate any possible contaminating genomic DNA, 1µg of RNA per tissue was treated with DNase I amplification grade (Life Technologies, Karlsruhe, Germany). Reverse transcription of RNA was performed using random primers (FirstStrand cDNA synthesis kit; Life Technologies). The hBD-4 TaqMan system consisted of the amplification primers: hBD-4 F, 5'-GGCAGTCCCATAACCACATATTC-3'; hBD-4 R, 5'-TGCTGCTATTAGCCGTTTCTCTT-3', and the dual-labeled fluorescent TaqMan probe hBD-4 P, 5'-(FAM) TGTCCAATTCAAATTCGCTTCTCACTGGA (TAMRA)-3', designed for the exon-intron boundary. In addition, normalization of the cDNA load to the housekeeping gene ribosomal 18S or human glyceraldehyde-3-phosphate dehydrogenase (GAODH) was performed. The 18S TaqMan system consisted of the primers 18S F: 5'-GAAACTGCGAATGGCTCATTAAA-3' and 18S R: 5'-CACAGTTATCCAAGTGGGAGAGG -3' and the probe 18S P: 5'-(FAM) TCAGTTATGGTTCCTTTGGTCGCTCGC (TAMRA)-3', whereas the GAPDH system contained the primers GAPDH F: 5'-CCTGCACCACCAACTGCTTA-3' and GAPDH R: 5'-CATGAGTCCTTCCACGATACCA-3' and the probe GAPDH P: 5'(FAM) CCTGGCCAAGGTCATCCATGACAAC (TAMRA)-3'. A standard curve was constructed by cloning the same fragment to be amplified by the TaqMan system into a pGEM-T vector (Promega) by using five serial dilutions. The concentration of this reference plasmid was measured spectrophotometrically and converted into number of copies/µl by using the formula: number of copies/µl = g/µl × (mol/660 g) × (1/N) ×6.023x10 23 , where 660 mol/g is the average molecular weight of a nucleotide pair, N is the number of nucleotide pairs (3000 bp for the plasmid plus the size of the insert), and 6.023 × 10 23 is Avogadro's number (number of copies/mol). The number of copies in each sample was calculated with respect to the calibration curve, which was run in triplicate with each analysis. Every PCR experiment also included two no-template control wells.
Cell culture and induction of hBD-4 expression
SAEC 6043 human small airway epithelial cells were cultured by standard procedures in SABM medium (BioWhittaker Europe, Taufkirchen, Germany). Cells were seeded at 1 × 10 5 cells per well into six-well tissue culture plates (Costar, Cambridge, MA). When 60-75% confluence was reached, cells were treated for 24 h with normal medium (control) or medium containing either 20 ng/ml IL-1α, 100 ng/ml IL-6, 10 ng/ml phorbol 12-myristate 13-acetate (PMA), 20 ng/ml TNF-α, or 40 ng/ml interferon-γ. The time-dependency of induction of hBD-4 by PMA was further analyzed at 30 min, and at 2, 6, 12, and 24 h. All cytokines used for stimulation were supplied by PeproTech (Rocky Hill, NJ). RNA was extracted immediately after stimulation and subsequently reverse-transcribed. The expression of hBD-4 was studied by real-time quantitative RT-PCR as described previously. Experiments were repeated at least three times, and similar results were obtained.
Human respiratory epithelial cells were isolated from large airways resected during surgery and cultivated in air/liquid interface cultures as described previously (13) . All procedures were approved by the Institutional Review Board of the University of Munich. Differentiated cultures were selected for experiments by measuring the transepithelial resistance R t by using an ohmmeter (EVOM, World Precision Instruments, Sarasota, FL). For bacterial challenge of the epithelial cultures, Pseudomonas aeruginosa PAO1 and Streptococcus pneumoniae ATCC 33400 were grown as described previously (13), and inocula of bacteria growing in log-phase were added to each well. The numbers of colony-forming units applied to the cultures are indicated in the figure legends. RNA was isolated after 6 h stimulation, and levels of gene expression were quantified by real-time RT-PCR.
Synthesis of the hBD-4 peptide
Because there is currently no direct information on the length of a natural hBD-4 peptide, we decided to synthesize a peptide that contains the β-defensin consensus and shows an N-and Cterminus analogous to known bioactive defensins. The chosen sequence starts with five amino acids before the first cysteine residue, because it is known that other β-defensins have an Nterminus consisting of at least four amino acid residues before Cys1 and the length may vary without significant influence on the antimicrobial activity (11, 13) . At the C-terminus, the sequence was cut after the third amino acid following the last cysteine residue, analogous to the length of hBD-2. The amino acid sequence ELDRICGYGTARCRKKCRSQEYRIGRCPNTYACCLRK represents the form of hBD-4 we synthesized. Synthetic hBD-4 was assembled using standard fluorenylmethoxycarbonyl chemistry on a preloaded TentaGel S PHB resin (Rapp Polymere, Tübingen, Germany) by using a 433A peptide synthesizer (Applied Biosystems) at a scale of 0.1 mmol. Activation of fluorenylmethoxycarbonyl-protected amino acids was carried out with 2-(1H-benzotriazole-1-y1)-1,1,3,3-tetramethyluronium hexafluorophosphate. Cysteine residues were trityl-protected. For cleavage and deprotection, the dry peptidyl resin was treated with trifluoroacetic acid/ethanedithiol/water 94:3:3 (vol) for 4 h at room temperature. The product was then precipitated by adding cold tert-butylmethylether. The crude material was dried, dissolved in water, filtered, and prepurified by preparative Vydac C18 HPLC (The Seperations Group, Hesperia, CA). The combined fractions containing the reduced product were subjected to oxidative folding at a peptide concentration of 0.1 mg/ml in 0.1 M NH 4 HCO 3 /2 mM EDTA (pH 8) with addition of cysteine and cystine at a concentration of 0.2 mg/ml each. The reaction was performed under N 2 atmosphere at 4°C for 30 h, and a dominating product was observed by analytical HPLC. The chromatographically homogeneous hBD-4 obtained from this mixture after purification by C18 HPLC was lyophilized. The molecular weight determined by electrospray mass spectrometry was 4367.1 Da (calculated: 4366.1 Da). The amino acid sequence was confirmed by automated Edman degradation on a 494 protein sequencer (Applied Biosystems). To determine the cysteine bonds of synthetic hBD-4, we subjected two samples of the peptide to proteolytic cleavage in the presence of trypsin (modified, sequencing grade, Boehringer Mannheim, Germany) and chymotrypsin (sequencing grade, Boehringer Mannheim) at 36°C for 4 h, and of endoproteinase Arg-C and chymotrypsin (both sequencing grade, Boehringer Mannheim) at 36°C for 5 h, respectively. The mixtures obtained were separated by HPLC, and the fractions were then analyzed by electrospray mass spectrometry. Fractions corresponding to peptides containing disulfides were subjected to sequence analysis.
Antimicrobial activity assays
Conventional inhibition zone assay on agar dishes and microbroth dilution assays were used to evaluate the antimicrobial activity, as previously described (13, 24) . The following microorganisms were purchased from Deutsche Sammlung für Mikroorganismen und Zellkulturen (Braunschweig, Germany): Saccharomyces cerevisiae ATCC9763, Staphylococcus aureus ATCC25923, Streptococcus pneumoniae ATCC33400, and Burkholderia cepacia ATCC17770. Staphylococcus carnosus TM300 was provided by F. Goetz (University of Munich). Escherichia coli BL21 was supplied by J. Alves (Hannover Medical School). Clinical isolates of Burkholderia cepacia were obtained from B. Grabein (University of Munich). Pseudomonas aeruginosa PAO1 was additionally included. The synthetic peptide MBI 28 (25) , the human cathelicidin LL-37 (26) , and hBD-3 were used as positive controls.
To evaluate a potential synergism between hBD-4 and other antibiotics, the checker-board dilution method was used (27) . Drugs were interpreted to be synergistic when the FIC index was < 0.5. The salt sensitivity of the antimicrobial activity of hBD-4 was evaluated using Staphylococcus carnosus TM300 in microdilution assays, which were carried out using different dilutions of hBD-4 and sodium chloride in tryptic soy broth medium.
In vitro chemotaxis and calcium mobilization
In vitro chemotaxis and analysis of changes of the cytosolic free calcium concentration were performed as described previously (7, 28) .
RESULTS
Analysis of the genomic and cDNA sequences of hBD-4
The peptide sequence of hBD-2 was used to perform a "basic local alignment search tool" (BLAST) search in the High Throughput Genomic (HTG) division of the GenBank in order to identify genomic sequences around this β-defensin at the chromosomal region 8p23. GenBank accession numbers AF202031, AF252831, AF189745, and AC074340 were found and subsequently screened for the presence of the β-defensin consensus pattern as described in Materials and Methods. The analysis of the clone AF202031 revealed a genomic sequence coding for the C-terminal region of a putative novel β-defensin, which was further found in several HTG clones available at GenBank. The full-length cDNA for hBD-4 was generated by RACE-PCR, showing a 216-bp open reading frame encoding a prepropeptide of 72 amino acids in length (Fig. 1A) . The corresponding peptide exhibited the presence of the β-defensin-specific pattern of six cysteine residues, although the amino acid sequence identity with hBD-1, hBD-2, and hBD-3 was only between 20-25%. Figure 1B shows the alignment of hBDs and mouse β-defensins cloned so far.
The genomic sequence of hBD-4 shows the classical structure of β-defensins, with two exons separated by a 4495-bp intron. Although the first exon encodes for most of the signal peptide, the second exon encodes for the end of the signal peptide and the propeptide (Fig. 2) . The analysis of the 1200-bp upstream of the first exon reveals a TATA boxless region and several AP-1 and GATA1 binding sites. No NF-κB or STAT binding sites are present at the 5'-flanking region of this gene.
Assignment of the disulfides of synthetic hBD-4
The product obtained from the chemical synthesis of hBD-4 was homogenous as proven by analytical HPLC, capillary zone electrophoresis, electrospray mass spectrometry, and sequence analysis, indicating that no disulfide isomers were present. Analysis of the disulfide bond pattern unambiguously revealed a cysteine connectivity, which was described for BNBD-12 (29) . Upon cleavage of hBD-4 with trypsin/chymotrypsin, two disulfide-containing peptides were generated, Cys 51 -Pro-Asn-Thr-Tyr connected to 58 , and in full agreement with the β-defensin-specific disulfide pattern (29) . In these experiments, only fragments that are in agreement with this disulfide pattern have been found.
hBD-4 exhibits a specific distribution pattern of expression
The distribution of hBD-4 transcripts in the human body was evaluated by the real-time quantitative RT-PCR (TaqMan) method. The highest hBD-4 expression was found in the testis. Gastric antrum also exhibits relatively high levels of hBD-4 expression, whereas in uterus, neutrophils, thyroid gland, lung, and kidney a low hBD-4 expression was found (Fig. 3A) . No detectable expression was observed in other tissues tested.
hBD-4 expression is induced by infection and PMA in lung epithelial cells
Because hBDs have been described to be either constitutively expressed or induced by infection or inflammation, we further investigated the effect of infection on the hBD-4 expression by realtime quantitative RT-PCR in human respiratory epithelial cells isolated from large airways resected during surgery and cultivated in air/liquid interface cultures. Basal hBD-4 mRNA levels increased 2-fold upon addition of heat-inactivated Pseudomonas aeruginosa, whereas 10 4 and 10 6 colony-forming units of Pseudomonas aeruginosa gave rise to 1.5-fold and 3.3-fold increases, respectively, and 10 6 colony-forming units of Streptococcus pneumoniae up-regulated the hBD-4 expression by 7-fold (Fig. 3B) . Furthermore, we investigated which inflammatory factors could be responsible for this up-regulation in SAEC 6043 small airway epithelial cells. The low basal expression of hBD-4 did not increase following 24 h of exposure to either IL-1α, IL-6, interferon-γ, or TNF-α. However, PMA treatment gave rise to a more than 60-fold increase of hBD-4 mRNA levels. The analysis of the temporal pattern of this up-regulation revealed that hBD-4 expression was not detectable after 30 min of PMA stimulation and that it was maximum at 12 h (Fig. 3C ).
hBD-4 is an endogenous salt-dependent antimicrobial peptide which exhibits synergism with other antibiotics
To evaluate the antimicrobial activity of hBD-4, we synthesized the predicted biologically active peptide by solid-phase chemistry. This hBD-4 peptide inhibited the growth of gram-positive Staphylococcus carnosus TM300, gram-negative Escherichia coli BL21, and yeast Saccharomyces cerevisiae ATCC9763 in a conventional radial diffusion test (data not shown).
The minimum hBD-4 concentration for growth inhibition was further tested by conventional dilution assays, with hBD-3, cathelicidin LL-37, and MBI 28 as positive controls. The MIC of hBD-4 was higher than 100 µg/ml for Escherichia coli BL21, Saccharomyces cerevisiae ATCC9763, Staphylococcus aureus ATCC25923, Streptococcus pneumoniae ATCC33400, and Burkholderia cepacia ATCC17770. In contrast, hBD-4 exhibited a strong antimicrobial activity against Staphylococcus carnosus TM300 (4.5 µg/ml) and, in particular, against Pseudomonas aeruginosa PAO1 (4.1 µg/ml). The ability of hBD-4 to inhibit the growth of Staphylococcus carnosus TM300 decreased 4-fold when sodium chloride concentration was increased from 0 to 25 mM, 8-fold when it increased to 50 mM, and more than 16-fold when it reached physiological concentrations (MIC >72 µg/ml).
Additional experiments were conducted to evaluate synergism between hBD-4 and the endogenous antimicrobial hBD-3 and lysozyme, an antibiotic also present in the gastrointestinal and respiratory tract, as well as the classical antibiotic ampicillin. Synergism was noted with lysozyme (FIC<0.5) against Staphylococcus carnosus TM300, whereas an additive effect that is close to synergism (FIC ∼0.6) was observed with hBD-3 for Staphylococcus carnosus TM300 and Escherichia coli BL21. A combination of hBD-4 and ampicillin showed no interactions (FIC ∼1).
hBD-4 is a chemoattractant for monocytes
The biological activity of hBD-4 was tested on cells involved in the innate immune response for its chemotactic and calcium mobilizing properties (Fig. 4) . hBD-4 induced significant but moderate migration of monocytes with a maximum response at 10 nM. The chemotactic activity of hBD-4 is thus very similar to that of hBD-3 in terms of potency and efficacy. No migration induced by hBD-4 was observed for neutrophils or eosinophils. Both hBD-4 and hBD-3 did not induce Ca 2+ mobilization, whereas fMLP or certain chemokines elicit a transient rise of free cytosolic calcium in monocytes, neutrophils, and eosinophils (data not shown).
DISCUSSION
In this study, we report the discovery of the fourth hBD, hBD-4. This novel hBD was found through the analysis of genomic sequences mapping at chromosome 8p23, the gene locus where the known α-and β-defensins are clustered. hBD-4 exhibited the same genomic organization as other β-defensins, with two exons flanking an intron of 4495 bp. The deduced prepropeptide exhibits a putative signal peptide followed by the six-cysteine motif characteristic for a β-defensin. In addition, synthetic hBD-4 peptide exhibits antimicrobial activity against different bacteria and yeast and induced migration of monocytes.
As in the sequences of murine defensins mBD-3 and mBD-4 (30, 31) , the spacing between the second and the third cysteine is reduced by one residue with respect to the sequences of hBD-1, hBD-2, and hBD-3. It is of interest that the sequence of hBD-4 also shows one amino acid less between the fourth and the fifth cysteine, confirming that the cysteine spacing may vary for other β-defensins yet to be discovered. These differences in the primary structures may cause slightly different three-dimensional structures, and this could imply different activities against the diverse classes of microorganisms that infect the tissues where these β-defensins are expressed.
The analysis of the promoter region of hBD-4 revealed no binding sites for NF-κB, which is an important inflammatory mediator, the binding sites of which are present in the promoters of the inducible β-defensins hBD-2, mBD-3, and TAP (30, 32) . Moreover, no STAT binding site, recently associated with the up-regulation of hBD-3 upon stimulation with interferon-γ (7), was found in the 5'-flanking region of this gene. In agreement with these data, hBD-4 expression did not increase after stimulation by IL-1α, IL-6, interferon-γ, or TNF-α, but it was increased more than 60-fold upon stimulation with PMA. Bacterial infection (especially by Streptococcus pneumoniae) and heat-inactivated Pseudomonas aeruginosa also up-regulated the hBD-4 gene. It is well known that PMA activates specific protein kinase C isoenzymes (33) , and some of them are activated in some cell types in response to LPS (34) and infection (35) . Taken together, these data suggest the hBD-4 induction is mediated by protein kinase C in airway epithelial cells.
The highest hBD-4 expression is observed in testis. These results are in agreement with the relatively high levels of hBD-3 expression in the genital tract (7) and may explain why bacterial testicular infections are, in contrast to prostate infections, extremely uncommon, although microbes can readily access male germ tissue through urethral entry. Unlike the other previously described hBDs, hBD-4 expression is restricted to a few tissues. A restricted pattern is also exhibited by mBD-4. The selectivity in both expression pattern and antimicrobial activity suggests that hBD-4 is best suited to act at the epithelial locations where it is expressed.
We have also confirmed synergistic effects of hBD-4 with lysozyme as well as a strong additive effect with hBD-3. Because epithelial surfaces never express a single antimicrobial substance, but a cocktail of them regulated by different mechanisms, their cooperative contribution to host defense is much more complex than just the sum of the activities of each individual molecule. The bactericidal activity of hBD-4 against Pseudomonas aeruginosa was more than sixfold stronger than that for any other known β-defensin. These data, together with the reinforcement of the antibiotic activity upon interaction with other antimicrobial molecules and the chemotactic activity on monocytes, suggest an important role for this β-defensin in innate immunity, especially in the respiratory tract. The chemotactic activity is independent from intracellular calcium mobilization as it has been shown for other chemoattractants such as BCA-1 (36). However, it has been reported that the antimicrobial potency of defensins might be inactivated in the high-salt environment of the cystic fibrosis airway surface fluid (37) . The salt sensitivity of hBD-4 reinforces the concept of a putative role for these peptides in lung pathogenesis of cystic fibrosis, with obvious implications for therapeutic approaches. It is intriguing that an effective combination of hBD-4 and other endogenous antimicrobials engineered to overcome salt sensitivity (38) may be administered into the airways of these patients, because the increasing resistance of microorganisms to classical antibiotics is a severe problem that requires the urgent development of new therapeutic approaches. 
